06.15
BEIJING, China, June 15, 2009 /PRNewswire-FirstCall via COMTEX/ — Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com is pleased to announce that its Mellow Hope Bio Chem China division has signed an agreement with Yunnan Walvax Biotech Co., Ltd on the issue of Haemophilus influenza type “B” conjugate vaccine.
Under the terms of the agreement Mellow Hope will be fully authorized to do the International marketing of Haemophilus influenza type “B” conjugate vaccine in the global market.
HTDS intends to begin the registration process in Chile, India, Indonesia, Egypt, and Russia, commencing in June 2009 with the brand name “MEVAC-Hib”.
Yunnan Walvax Biotech Co., Ltd is the second biggest manufacturer of Haemophilus influenza type b conjugate vaccine in China.
No Comment.
Add Your Comment